Akeso Inc. (9926.HK) ("Akeso", "the Company") released its 2024 annual report, emphasizing the company's key achievements in drug research, clinical development, and commercialization.

Key Phase III Trials in NSCLC : Ivonescimab monotherapy vs ... improving and contributing to the global IO cancer treatment landscape. Breakthrough Bispecifics Enter NRDL, Paving the Way for ...

The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced ...

This positions Akeso as a key innovator in next-generation cancer immunotherapy, improving and contributing to the global IO cancer treatment landscape ... locally advanced or metastatic non-squamous ...

Sydney, Australia Friday, March 28, 2025, 18:00 Hrs [IST] ...

Merus leads biotech with its innovative antibody platforms, strong financials, and promising petosemtamab targeting cancer.

Southeast Asia is a region with a high incidence of NPC, and we are proud to introduce this groundbreaking therapy to address ...

Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine , Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild ...